1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Estimated Apr 29 2026 per aggregator, but topic was withdrawn after one day pending SBIR reauthorization; not confirmed open.
SBIR DHA26BZ01-DV005: Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II) is sponsored by Defense Health Agency (DHA). SBIR DHA26BZ01-DV005 is a grant from the Defense Health Agency (DHA) that funds small businesses developing novel small molecules with broad-spectrum antifungal properties safe for use in human patients.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II) - SBIR DHA26BZ01-DV005 — BW&CO Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II) - SBIR DHA26BZ01-DV005 Active specific topic DSIP This topic was temporarily posted by the Department of War SBIR Program on March 2nd 2026 and removed the following day.
We believe this topic is planned to be released once the SBIR program is reauthorized; however, this topic may ultimately be modified or withdrawn. Notify Me When This is Released This topic is intended for technology proven ready to move directly into Phase II and accepts Direct to Phase II proposals only.
The proposed research will focus on identifying compounds with broad-spectrum activity against clinically relevant fungal pathogens while minimizing toxicity to humans. The primary objective is to identify a small molecule with fungicidal properties that are safe for human use, with FDA clearance. Fungal infections represent a growing global health challenge, particularly among immuno-compromised individuals.
Invasive fungal infections caused by pathogens such as Candida species, Aspergillus species, Fusarium species, and Mucor species are associated with high morbidity and mortality rates. Fungal infections are associated with 130k hospitalizations, 13 million outpatient visits, and result in a financial burden of $19 billion on the civilian health care sector.
Fungal wound infections in particular are also growing challenge for the military. Despite the availability of antifungal agents, current treatments are often limited by toxicity, drug resistance, and narrow-spectrum activity. The emergence of multidrug-resistant fungal strains, such as Candida auris, has further exacerbated the need for novel antifungal therapies.
Small molecules with antifungal properties offer a promising avenue for addressing these challenges. Their ability to target specific fungal pathways, combined with the potential for oral bioavailability and low manufacturing costs, makes them ideal candidates for therapeutic development.
However, significant scientific and technical hurdles remain with the discovery and optimization of small molecules that are both effective against fungal pathogens and safe for human use. Qualified proposals should identify small molecules with antifungal properties from an existing library.
These small molecules should be active against all of the following fungi: Fusarium species, Aspergillus species, Candida auris, or Mucorales species. Qualified molecules will have antifungal activity at nanomolar concentrations. Further, these small molecules must have a cytotoxicity profile similar, or better than Amphotericin B.
If you can achieve the objective above better than any other company on the market, you have a very high-likelihood of success and should apply. Who is eligible to apply? Any company that meets the following criteria: U.S.-owned and controlled.
500 or fewer employees (including affiliates) 1) End-to-end support including, strategy, writing of the full proposal, and administrative & compliance support. 2) Proposal strategy and review. 3) Administrative & compliance support.
Request to talk with a member of our team by completing the form below: Biotech healthtech Medtech Defense & Dual Use Technology DHA https://www. bwcoconsulting. com Military Working Dog Whole Blood Product or Substitute - SBIR DHA26BZ01-NV001 Low-Cost, Phased Array Antennas for Collaborative Jamming in sUAS Swarms - SBIR Topic DAF26TZ01-NV004
According to the current listing, eligibility includes: Small business concerns (SBCs) organized for profit, with a place of business in the United States; at least 51% owned and controlled by one or more U. S. citizens or permanent resident aliens. Confirm the full requirements in the official notice before applying.
The current listing shows up to $1,750,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
The published deadline was June 3, 2026, which has passed. Check the official notice for any future application windows before investing time in a proposal.
SBIR DHA26BZ01-DV005: Development of Small Molecules with Antifungal Properties for Safe Use in Human Patients (Direct to Phase II) is funded by Defense Health Agency (DHA). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
BAA for Extra Mural Medical Research - HT942523SBAA1 is sponsored by Defense Health Agency (DHA). The Defense Health Agency is seeking proposals for funding in support of research areas including Military Infectious Diseases (R&D of solutions for prevention, treatment, and diagnosis), Combat Casualty Care (R&D of products to stop blood loss, resuscitate, and limit consequenc…
DHA Small Business Innovation Research (SBIR) Program is sponsored by Defense Health Agency (DHA). The DHA SBIR program funds biomedical and health-focused technologies that enhance medical readiness, clinical care delivery, force health protection, operational medicine, and military healthcare modernization. This includes digital health systems, AI-enabled triage, portable medical devices, and physiological monitoring tools for austere environments.
HRSA-27-006 and HRSA-27-007 post September 18, 2026 and both close October 19 — $711.4 million across 189 awards for service areas that already have a health center in them. The incumbent is defending. Everyone else is holding a free option.
Read articleCDMRP's FY26 portfolio funds 34 programs, and October 2026 is dense with full-application deadlines: PRCRP October 5, PCRP October 7, MRP October 14. Every one of them is gated behind a pre-application that closed months earlier. Here is what that two-step structure actually costs applicants, and how to be inside the gate for FY27.
Read articleUSDA has obligated roughly $1 billion in emergency funds against New World screwworm and awarded $105 million to 40 Grand Challenge projects from 226 proposals. On September 2, 2026, DARPA pre-released a $2.1 million SBIR topic for networked screwworm detection. Four funding streams, four eligibility regimes, four clockspeeds — and most applicants only know about one.
Read article